# A Study of PYX-201 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct05720117/  
OnCo record `nct05720117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Micvotabart pelidotin run by Pyxis Oncology, Inc, now recruiting.

## Summary

A Study of PYX-201 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05720117 by Pyxis Oncology, Inc, with 330 participants planned, started 2023-03-14, primary completion expected 2027-04-25. Conditions recorded: Solid Tumor, Advanced Solid Tumor. Interventions recorded: PYX-201.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05720117
- Phase: 1
- Setting: A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors
- Sponsor: Pyxis Oncology, Inc
- Enrolled: 330

## Sources

- ClinicalTrials.gov NCT05720117: https://clinicaltrials.gov/study/NCT05720117

## Connected records

- drugs: [Micvotabart pelidotin](https://onco.cc/drugs/micvotabart-pelidotin/)
- companies: [Pyxis Oncology](https://onco.cc/companies/pyxis-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct05720117.json